Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.

"Disclosures: This manuscript has been read and approved by all authors. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The authors and peer reviewers of this paper report no conflicts of interest. The authors confirm that they have permission to reproduce any copyrighted material."

"Dr. Pal’s efforts are supported by the NIH Loan Repayment Plan (LRP), the CBCRP 15IB-0140 (California Breast Cancer Research Program Junior IDEA Award) and NIH K12 2K12CA001727-16A1. Dr. Figlin acknowledges the ongoing support of Kure It! (a Kidney Cancer Research Fund), the generous support of the Hoeven family, and Richard and Nancy Bloch Kidney Cancer Research Funds."